Evaluate Safety News Today

US patients aged 10 years and older can now benefit from FARXIGA for type-2 diabetes Approval based on results from T2NOW, one of the largest pediatric type-2 diabetes Phase III trials to date ...

Lenovo to Raise $2 Billion Via Convertible Bonds Lenovo Group is raising US$2.0 billion by issuing convertible bonds to a unit of Saudi Arabias sovereign-wealth fund, which could result in the...

OpenAI Forms New Committee to Evaluate Safety, Security OpenAI formed a safety and security committee after recently becoming embroiled in a legal battle over a new voice assistant in its...

OpenAI Forms New Committee to Evaluate Safety, Security The move comes after the ChatGPT creator was involved in a legal standoff with Scarlett Johansson over the release of a new female voice...

Adam Neumann Gives Up Bid to Buy Back WeWork The co-founder of the shared-workspace company says WeWorks bankruptcy plan appears unrealistic. OpenAI Forms New Committee to Evaluate Safety,...

Hess Shareholders Approve $53 Billion Merger With Chevron Stockholders approval clears one hurdle for the tie-up to happen but a challenge by Exxon makes the final outcome uncertain. Adam...

Hess Shareholders Give Approval to $53 Billion Merger With Chevron Investors green light clears one hurdle for the tie-up to happen but a challenge by Exxon makes the final outcome uncertain....

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric and adult patients Gastroenteropancreatic neuroendocrine...

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17)...

This approval makes lutetium Lu177 the first therapy to be approved for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients.